Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed

$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TEVA alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $TEVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TEVA

DatePrice TargetRatingAnalyst
7/10/2024$20.00Hold → Buy
Argus
3/8/2024$14.00Underweight → Neutral
JP Morgan
2/12/2024$12.00 → $19.00Neutral → Overweight
Piper Sandler
1/23/2024$10.00 → $14.00Hold → Buy
Jefferies
1/3/2024$8.00 → $12.00Underweight → Neutral
Piper Sandler
12/18/2023$13.00Buy
HSBC Securities
11/27/2023$11.00 → $13.00Neutral → Buy
UBS
7/6/2023$7.00 → $8.00Sell → Neutral
UBS
More analyst ratings

$TEVA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

    More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY® (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trialTeva continues its commitment to generating clinical insights that help advance and support optimal treatment for individuals living with schizophrenia PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

    TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 hou

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva Releases Q1 2025 Aide Memoire

    TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. Going forward, it is Teva's intention to provide this information towards the end of each quarter. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global bio

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TEVA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TEVA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TEVA
 SEC Filings

See more

$TEVA
 Leadership Updates

Live Leadership Updates

See more

  • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva Announces Changes to Executive Management Team

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a h

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TEVA
 Financials

Live finance-specific insights

See more

  • Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

    TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 hou

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva Releases Q1 2025 Aide Memoire

    TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. Going forward, it is Teva's intention to provide this information towards the end of each quarter. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global bio

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

    New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvementFindings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi today presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV'574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for

    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TEVA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more